Nant Capital

Nant Capital
NHS Confederation · CC BY 2.0 · source
Name	Nant Capital
Type	Private investment firm
Founder	Patrick Soon-Shiong
Founded	2010s
Headquarters	Los Angeles, California
Industry	Private equity, venture capital, asset management
Key people	Patrick Soon-Shiong, other executives

Nant Capital is a private investment firm associated with a group of companies founded by Patrick Soon-Shiong. It operates across private equity, venture capital, and asset-management activities, making investments in biotechnology, health care, technology, and media. The firm is part of a broader constellation of enterprises linked to Soon-Shiong, with operational ties to clinical enterprises, research initiatives, and media holdings.

History

The firm emerged from the expansion of Patrick Soon-Shiong's business activities following his tenure at companies such as Abraxis BioScience, American Pharmaceutical Partners, and interactions with institutions like Cedars-Sinai Medical Center. Early moves coincided with acquisitions and corporate reorganizations involving Allergan-era assets and transactions in the biopharmaceutical sector. Nant Capital's development paralleled the creation of affiliated entities such as NantWorks and collaborations with research centers exemplified by linkages to The Broad Institute and university medical centers. Over time, investment activity intersected with high-profile purchases connected to the Los Angeles Times and other Tribune Publishing assets, reflecting a diversification into media and information technology platforms.

Investments and Portfolio

Nant Capital's portfolio has included stakes in companies across biotechnology, genomics, pharmaceuticals, medical devices, digital health, and media ventures. Notable affiliated investments have been reported in firms developing diagnostics related to next-generation sequencing and precision oncology linked to clinical programs at institutions such as UCLA Health and Mount Sinai Health System. The firm has been associated with capital flows into enterprises that partnered with legacy pharmaceutical companies like Pfizer and Johnson & Johnson through licensing, co-development, or asset sales. Additionally, Nant-associated capital participated in transactions involving technology firms that intersect with Cloud computing providers and telemedicine platforms, aligning with trends seen at corporations such as Amazon (company) and Google in health initiatives. The portfolio reflects a blend of early-stage venture positions and later-stage private-equity style investments, occasionally participating in consortiums with firms like Blackstone, KKR, and Bain Capital.

Business Model and Strategy

The firm's strategy emphasizes convergence investing at the intersection of biotech innovation and information technologies. It typically seeks to integrate portfolio company capabilities with clinical networks and research collaborations involving entities such as Johns Hopkins Medicine and Massachusetts General Hospital. Capital deployment has combined direct equity investments, strategic partnerships, and platform-building approaches that leverage intellectual property originating from academic spinouts linked to institutions like Harvard University and Stanford University. Strategic goals include accelerating commercialization of therapeutics and diagnostics, scaling digital health platforms, and consolidating complementary assets to create vertically integrated service models reminiscent of conglomerates such as Roche and Medtronic.

Leadership and Organization

Leadership centers on Patrick Soon-Shiong, a physician-entrepreneur known for roles at Horizon Therapeutics-era companies and for philanthropy tied to biomedical research institutions including Johns Hopkins University and Cedars-Sinai. The organizational structure includes investment professionals with backgrounds at firms like Goldman Sachs, Morgan Stanley, and Evercore, alongside scientific officers recruited from research institutions such as Salk Institute and Scripps Research. Governance practices reflect private investment firm norms with boards populated by industry executives and academic advisors from organizations like National Institutes of Health collaborations and consortia involving Bill & Melinda Gates Foundation-style philanthropic ventures.

Regulatory and Legal Issues

Activities have intersected with regulatory frameworks administered by agencies such as the Food and Drug Administration and oversight bodies including the Securities and Exchange Commission, given investments in regulated therapeutics and securities transactions. The firm's transactions and affiliated operations have been subject to scrutiny in contexts involving corporate governance and media ownership rules similar to precedent cases involving McClatchy and Gannett. Legal and regulatory challenges have at times involved dispute resolution mechanisms comparable to matters adjudicated in federal courts and arbitration forums, with external counsel experienced in transactions with parallels to those handled by firms like Skadden, Arps, Slate, Meagher & Flom and Latham & Watkins.

Category:Private equity firms in the United States